News, views and contacts from the global Pharmaceutical industry
 

News Archive

Archive of industry news from the global pharmaceutical industry

News By Date

October 2014

Top

AstraZeneca’s type 2 diabetes treatment Xigduo XR obtains FDA approval
31 October 2014 British-Swedish drugmaker AstraZeneca has received approval from US Food and Drug Administration (FDA) for its once-daily Xigduo XR to treat adult patients with type 2...

Pfizer’s Trumenba gets FDA accelerated approval to treat Meningococcal B disease
31 October 2014 US-based drugmaker Pfizer has received accelerated approval from US Food and Drug Administration (FDA) for its Trumenba to treat Meningococcal B disease in adolescents and young...

GSK launches bronchodilator treatment Incruse Ellipta in UK
30 October 2014 British drug-maker GlaxoSmithKline (GSK) has introduced a new once-daily bronchodilator treatment, Incruse Ellipta (umeclidinium) in the...

Qiagen and Astellas Pharma to develop companion diagnostics for cancer and other diseases
30 October 2014 Qiagen has signed a master collaboration agreement with global pharmaceutical company Astellas Pharma to develop and commercialise companion diagnostics, combined with the latter's drugs for use...

Merck’s Keytruda receives FDA breakthrough therapy designation to treat NSCLC
29 October 2014 Merck has received breakthrough therapy designation from US Food and Drug Administration (FDA) for its Keytruda (pembrolizumab) to treat patients with epidermal growth factor receptor...

Johnson & Johnson unveils Asia Pacific Innovation Center in Shanghai, China
29 October 2014 Johnson & Johnson Innovation has launched the Asia Pacific Innovation Center in Shanghai, China, with satellites in Singapore, Australia and...

EU IMI launches new consortium to develop economic models for pharmaceutical industry
28 October 2014 A new European consortium Driving Reinvestment in research and development and Responsible Antibiotic Use (Drive AB) has been launched, to deal with the growing global threat of antibiotic...

Australia’s CSL to buy Novartis influenza vaccine business for $275m
28 October 2014 Australia-based CSL has signed an agreement to acquire the global influenza vaccine business from Swiss drug-maker Novartis, for...

EMA committee recommends AstraZeneca’s Lynparza to treat ovarian cancer
27 October 2014 British-Swedish drug maker AstraZeneca has received positive feedback for its Lynparza (olaparib) from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use...

UK to invest £230m in new technologies research for various diseases
27 October 2014 A partnership led by Medical Research Council (MRC) will invest £230m in new technologies to identify causes for diseases such as cancer and dementia. The partneship will also focus on speeding...

Ipsen to market telotristat etiprate outside North America and Japan
24 October 2014 France-based Ipsen have entered an exclusive licensing agreement with US-based Lexicon Pharmaceuticals to market telotristat etiprate outside of North America and...

Roche to invest $3bn to develop Basel site in Switzerland
24 October 2014 Roche is set to invest more than CHF3bn ($3.14bn) to develop a new research and development centre, upgrade infrastructure and renovate the existing office building at its Basel site in...

FDA accepts Eisai’s sNDA to review antiepileptic drug Fycompa
23 October 2014 Japan-based Eisai has obtained approval for review from US Food and Drug Administration (FDA) for its antiepileptic drug Fycompa...

Johnson & Johnson invests $200m to accelerate Ebola vaccine programme
23 October 2014 US-based Johnson & Johnson (J&J) have announced an investment of more than $200m, in a bid to speed up the Ebola vaccine programme at its Janssen Pharmaceutical...

FDA accepts Merck and Sanofi’s BLA to review paediatric hexavalent vaccine
22 October 2014 Merck and Sanofi Pasteur have received approval for review from US Food and Drug Administration (FDA) for investigational paediatric hexavalent vaccine,...

Baxter introduces subcutaneous immunoglobulin treatment Hyqvia in US
22 October 2014 Baxter International and Halozyme Therapeutics have announced the launch of Hyqvia in the US, a subcutaneous immunoglobulin treatment for adult patients with primary immunodeficiency...

Apricus obtains US rights of urological treatment fispemifene from Forendo
21 October 2014 Apricus Biosciences has secured US development and commercialisation rights for a selective estrogen receptor modulator (SERM), fispemifene, from Finland-based Forendo...

Amgen sues Sanofi and Regeneron over patent infringement in US
21 October 2014 US-based Amgen has filed a case against Sanofi and Aventisub, formerly doing business as Aventis Pharmaceuticals and Regeneron Pharmaceuticals, in the US District Court of Delaware, over...

Pharmacyclics’ Imbruvica receives European approval for two blood cancers
20 October 2014 US-based Pharmacyclics has received marketing approval from the European Commission (EC) for its Imbruvica (ibrutinib) to treat adult patients with relapsed or refractory mantle cell lymphoma...

Sanofi Pasteur and Immune Design to develop vaccine for herpes simplex virus
20 October 2014 Vaccines division Sanofi Pasteur has partnered with clinical-stage immunotherapy company Immune Design to develop herpes simplex virus (HSV) immune therapy....

Ranbaxy to pay $40m to settle overcharging Texas Medicaid programme litigation
17 October 2014 India-based drug maker Ranbaxy Laboratories has agreed to pay $39.75m to settle litigation about its participation in Texas Medicaid, a US health care programme for people with low incomes....